5-Methylthiophene-2-carbothiamide | 24662-28-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 5-Methylthiophene-2-carbothiamide
• 英文别名: 5-methyl-thiophene-2-thiocarboxylic acid amide；5-Methylthiophene-2-carbothioamide
• CAS: 24662-28-0
• 化学式: C₆H₇NS₂
• mdl: MFCD11179444
• 分子量: 157.26
• InChiKey: XDQJZGFICZDEGM-UHFFFAOYSA-N

物化性质

• 沸点：
  279.6±42.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Methylthiophene-2-carbothiamide 、 2-氯乙酰乙酸乙酯 以 丙醇 为溶剂， 反应 4.0h， 生成 ethyl 4-methyl-2-(5-methyl-thiophen-2-yl)-thiazole-5-carboxylate
  参考文献：
  名称：

  PYRAZOLE COMPOUNDS AND USE THEREOF

  摘要：

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。

  公开号：

  US20090036450A1
• 作为产物：
  描述：

  5-甲基噻吩-2-羰酰氯 在 劳森试剂 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 5-Methylthiophene-2-carbothiamide
  参考文献：
  名称：

  3H-1,2,4-Dithiazol-3-one compounds as novel potential affordable antitubercular agents

  摘要：

  Small molecules with oxathiazol-2-one moiety were recently reported as potent inhibitors of Mycobacterium bovis var. bacilli Calmette-Guerin (BCG), among which HT1171 was the most potent and selective proteasome inhibitor. Herein we synthesized a series of novel compounds by bioisosteric replacement of the oxathiazol-2-one ring with 3H-1,2,4-dithiazol-3-one, and also fifteen 1,3,4-oxathiazol-2-one molecules in order for potency comparison and structure-activity relationship elucidation since their antibacterial effects on the virulent strains were not evaluated before. All the compounds were assessed for antitubercular activities on the virulent H37Rv strain by a serial dilution method. Among the tested compounds, 3H-1,2,4-dithiazol-3-one compound 4n was found to be the most active with a lowest MIC90 value of 1 mu g/mL. Furthermore, the cytotoxicities of all the compounds against normal human liver cell line L02 were determined by an MTT method. Compound 4n displayed a lower inhibitory ratio than HT1171 at the concentration of 100 mu M, indicating its better safety profile. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.065

文献信息

• Synthesis and platelet aggregation inhibitory activity of diphenylazole derivatives. I. Thiazole and imidazole derivatives.
  作者：Norihiko SEKO、Kohichiro YOSHINO、Koichi YOKOTA、Goro TSUKAMOTO

  DOI：10.1248/cpb.39.651

  日期：——

  Diphenylimidazole and diphenylthiazole derivatives were synthesized and tested as inhibitors of platelet aggregation in in vitro experiments with the rabbit. Diphenylthiazole derivatives (10) were more potent than diphenylimidazole derivatives (4) in inhibiting arachidonic acid-induced platelet aggregation of rabbit platelet-rich plasma. Two diphenylimidazole and eight diphenylthiazole derivatives were evaluated for ex vivo arachidonic acid and collagen-induced platelet aggregation inhibitory activity using guinea pigs. In these compounds, 4, 5-bis(4-methoxyphenyl)-2-(1, 5-dimethyl-2-pyrrolyl)thiazole (10n) showed strong activity in vitro and ex vivo. The ex vivo activity of 10n was 200 times stronger than that of aspirin. The mechanism of the activity of 10n was the inhibition of cyclo-oxygenase.

  合成了二苯基咪唑和二苯基噻唑衍生物，并在兔子的体外实验中将其作为血小板聚集抑制剂进行了测试。在抑制花生四烯酸诱导的兔子富血小板血浆血小板聚集方面，二苯基噻唑衍生物（10）比二苯基咪唑衍生物（4）更有效。用豚鼠评估了两种二苯基咪唑和八种二苯基噻唑衍生物对花生四烯酸和胶原蛋白诱导的血小板聚集的体内外抑制活性。在这些化合物中，4, 5-双（4-甲氧基苯基）-2-（1, 5-二甲基-2-吡咯基）噻唑（10n）在体外和体内均表现出很强的活性。10n 的体内外活性比阿司匹林强 200 倍。10n 的活性机制是抑制环氧化酶。
• PYRAZOLES AND USE THEREOF AS DRUGS
  申请人：Japan Tobacco Inc.

  公开号：EP2096111A1

  公开（公告）日：2009-09-02

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specification.

  本发明的吡唑化合物由以下通式（I）表示。本发明的吡唑化合物或其盐或其溶液能有效抑制肝糖原磷酸化酶，因此可用作糖尿病的治疗或预防药物。 其中各符号表示如说明书所述。
• THIAZOLE COMPOUND AND PREPARATION METHOD AND USE THEREOF
  申请人：Shanghai Theorion Pharmaceutical Co., Ltd.

  公开号：EP2708534B1

  公开（公告）日：2017-07-12
• 3H-1,2,4-Dithiazol-3-one compounds as novel potential affordable antitubercular agents
  作者：Jianzhong Yang、Weiyi Pi、Li Xiong、Wei Ang、Tao Yang、Jun He、Yuanyuan Liu、Ying Chang、Weiwei Ye、Zhenling Wang、Youfu Luo、Yuquan Wei

  DOI：10.1016/j.bmcl.2012.12.065

  日期：2013.3

  Small molecules with oxathiazol-2-one moiety were recently reported as potent inhibitors of Mycobacterium bovis var. bacilli Calmette-Guerin (BCG), among which HT1171 was the most potent and selective proteasome inhibitor. Herein we synthesized a series of novel compounds by bioisosteric replacement of the oxathiazol-2-one ring with 3H-1,2,4-dithiazol-3-one, and also fifteen 1,3,4-oxathiazol-2-one molecules in order for potency comparison and structure-activity relationship elucidation since their antibacterial effects on the virulent strains were not evaluated before. All the compounds were assessed for antitubercular activities on the virulent H37Rv strain by a serial dilution method. Among the tested compounds, 3H-1,2,4-dithiazol-3-one compound 4n was found to be the most active with a lowest MIC90 value of 1 mu g/mL. Furthermore, the cytotoxicities of all the compounds against normal human liver cell line L02 were determined by an MTT method. Compound 4n displayed a lower inhibitory ratio than HT1171 at the concentration of 100 mu M, indicating its better safety profile. (C) 2012 Elsevier Ltd. All rights reserved.
• PYRAZOLE COMPOUNDS AND USE THEREOF
  申请人：Takagi Masaki

  公开号：US20090036450A1

  公开（公告）日：2009-02-05

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。